Evolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression

Table 3 Anxiety scores and treatment response, n (%)/mean ± SD

Outcome measure	Intensive group (n = 72)	Standard group (n = 72)	P value
HAMA total score
Baseline	17.8 ± 4.0	17.3 ± 3.8	0.436
Week 12	11.2 ± 2.8	14.5 ± 3.3	< 0.001
Week 24	7.2 ± 2.1	11.8 ± 3.0	< 0.001
HAMD-17 response
Week 12	45 (62.5)	27 (37.5)	0.002
Week 24	57 (79.2)	36 (50.0)	< 0.001
HAMD-17 remission
Week 12	21 (29.2)	9 (12.5)	0.013
Week 24	42 (58.3)	23 (31.9)	0.001

HAMA: Hamilton Anxiety Rating Scale; HAMD-17: 17-item Hamilton Depression Rating Scale.